Nov. 30 - Moderna takes a 94% effective vaccine to the FDA | Biogen, Sage defend their brain drug alliance
Biogen stocks up on Sage's brain drugs in $3B deal; FAA says first flight shipping coronavirus vaccine takes off; The coronavirus vaccine frontrunners are advancing quickly. Here's where they stand.
Biogen and Sage each face challenges. While executives from both companies said the deal could provide a boost, investors don't appear to be sold just yet.
Moderna's shot was 94% effective against COVID-19 at a final study analysis, while Novavax disclosed another delay to initiation of a large trial in the U.S.
BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships.
BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries.
This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc.. 1575 Eye St NW, 4th Floor, Washington, DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.
No comments:
Post a Comment